Ranolazine
Active ingredient: Ranolazine
In short: Ranolazine extended-release tablets is indicated for the treatment of chronic angina. Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
What is Ranolazine used for?
Ranolazine extended-release tablets is indicated for the treatment of chronic angina.
Ranolazine extended-release tablets may be used with beta-blockers, nitrates, calcium channel blockers, anti- platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers.
Ranolazine dosage
Initiate ranolazine extended-release tablets dosing at 500 mg twice daily and increase to 1,000 mg twice daily, as needed, based on clinical symptoms. Take ranolazine extended-release tablets with or without meals. Swallow ranolazine extended-release tablets whole; do not crush, break, or chew.
The maximum recommended daily dose of ranolazine extended-release tablets is 1,000 mg twice daily.
If a dose of ranolazine extended-release tablets is missed, take the prescribed dose at the next scheduled time; do not double the next dose.
Dose adjustments may be needed when ranolazine extended-release tablets is taken in combination with certain other drugs
.
Limit the maximum dose of ranolazine extended-release tablets to 500 mg twice daily in patients on moderate CYP3A inhibitors such as diltiazem, verapamil, and erythromycin. Use of ranolazine extended-release tablets with strong CYP3A inhibitors is contraindicated
.
Use of P-gp inhibitors, such as cyclosporine, may increase exposure to ranolazine extended-release tablets. Titrate ranolazine extended-release tablets based on clinical response
.
How to take Ranolazine — instructions & advice from the label
Advise the patient to read the FDA-approved patient labeling (Patient Information).
Inform patients that ranolazine extended-release tablets will not abate an acute angina episode.
Strong CY3PA Inhibitors, CYP3A Inducers, Liver Cirrhosis
Inform patients that ranolazine extended-release tablets should not be used with drugs that are strong CYP3A inhibitors (e.g., ketoconazole, clarithromycin, nefazodone, ritonavir)
.
Inform patients that ranolazine extended-release tablets should not be used with drugs that are inducers of CYP3A (e.g., rifampin, rifabutin, rifapentine, barbiturates, carbamazepine, phenytoin, St. John's wort)
.
Inform patients that ranolazine extended-release tablets should not be used in patients with liver cirrhosis
[
,
Use in Specific Populations (8.6)].
Moderate CYP3A Inhibitors, P-gp Inhibitors, Grapefruit Products
Advise patients to inform their physician if they are receiving drugs that are moderate CYP3A inhibitors (e.g., diltiazem, verapamil, erythromycin)
.
Advise patients to inform their physician if they are receiving drugs that are P-gp inhibitors (e.g., cyclosporine)
. …
Warnings & precautions
Do not take this medicine if: Ranolazine extended-release tablets is contraindicated in patients:
Taking strong inhibitors of CYP3A
Taking inducers of CYP3A
With liver cirrhosis
Ranolazine blocks I
Krand prolongs the QTc interval in a dose-related manner.
Clinical experience in an acute coronary syndrome population did not show an increased risk of proarrhythmia or sudden death
.
However, there is little experience with high doses (>1,000 mg twice daily) or exposure, other QT- prolonging drugs, potassium channel variants resulting in a long QT interval, in patients with a family history of (or congenital) long QT syndrome, or in patients with known acquired QT interval prolongation.
Acute renal failure has been observed in some patients with severe renal impairment (creatinine clearance [CrCL] <30 mL/min) while taking ranolazine extended-release tablets. If acute renal failure develops (e.g., marked increase in serum creatinine associated with an increase in blood urea nitrogen [BUN]), discontinue ranolazine extended-release tablets and treat appropriately
.
Monitor renal function after initiation and periodically in patients with moderate to severe renal impairment (CrCL <60 mL/min) for increases in serum creatinine accompanied by an increase in BUN.
Ranolazine side effects
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
A total of 2018 patients with chronic angina were treated with ranolazine in controlled clinical trials. Of the patients treated with ranolazine extended-release tablets, 1026 were enrolled in three double- blind, placebo-controlled, randomized studies (CARISA, ERICA, MARISA) of up to 12 weeks’duration. In addition, upon study completion, 1251 patients received treatment with ranolazine extended-release tablets in open-label, long-term studies; 1227 patients were exposed to ranolazine extended-release tablets for more than 1 year, 613 patients for more than 2 years, 531 patients for more than 3 years, and 326 patients for more than 4 years.
At recommended doses, about 6% of patients discontinued treatment with ranolazine extended-release tablets because of an adverse event in controlled studies in angina patients compared to about 3% on placebo. The most common adverse events that led to discontinuation more frequently on ranolazine extended-release tablets than placebo were dizziness (1.3% versus 0.1%), nausea (1% versus 0%), asthenia, constipation, and headache (each about 0.5% versus 0%). Doses above ,1,000 mg twice daily are poorly tolerated. …
Drug interactions
Strong CYP3A Inhibitors
Do not use ranolazine extended-release tablets with strong CYP3A inhibitors, including ketoconazole, itraconazole, clarithromycin, nefazodone, nelfinavir, ritonavir, indinavir, and saquinavir
.
Moderate CYP3A Inhibitors
Limit the dose of ranolazine extended-release tablets to 500 mg twice daily in patients on moderate CYP3A inhibitors, including diltiazem, verapamil, erythromycin, fluconazole, and grapefruit juice or grapefruit-containing products
.
P-gp Inhibitors
Concomitant use of ranolazine extended-release tablets and P-gp inhibitors, such as cyclosporine, may result in increases in ranolazine concentrations. Titrate ranolazine extended-release tablets based on clinical response in patients concomitantly treated with predominant P-gp inhibitors such as cyclosporine
.
CYP3A Inducers
Do not use ranolazine extended-release tablets with CYP3A inducers such as rifampin, rifabutin, rifapentine, phenobarbital, phenytoin, carbamazepine, and St. John's wort
.
Drugs Metabolized by CYP3A
Limit the dose of simvastatin in patients on any dose of ranolazine extended-release tablets to 20 mg once daily, when ranolazine is co-administered. …
About this medicine
Ranolazine extended-release tablets is available as a film-coated, non-scored, extended-release tablet for oral administration.
Ranolazine is a racemic mixture, chemically described as 1-piperazineacetamide,
N-(2,6-dimethylphenyl)-4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]-, (±)-. It has an empirical formula of C
24H
33N
3O
4, a molecular weight of 427.54 g/mole, and the following structural formula:
Ranolazine is a white to off-white colored powder. Ranolazine is soluble in dichloromethane and soluble in methanol.
Ranolazine extended-release tablets contain 500 mg or 1,000 mg of ranolazine and the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, methacrylic acid–ethyl acrylate copolymer, sodium hydroxide pellets, hydroxypropyl methylcellulose, magnesium stearate, hypromellose, titanium dioxide, macrogol, triacetin, iron oxide yellow.
Methacrylic acid–ethyl acrylate copolymer contains 0.7%, Sodium Lauryl sulfate Ph. Eur. / NF and 2.3% Polysorbate 80 Ph. Eur. / NF on solid substance. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID a624dc7f-921d-4554-a813-f72dca0133c3. Read the full official label on DailyMed.
Related medicines
Atorvastatin Amlodipine Lisinopril Losartan Metoprolol Rosuvastatin Simvastatin Spironolactone